Science Letter on the risks of extending U.S. tariffs to pharmaceuticals

Just published in Science: our Letter on the risks of extending U.S. tariffs to pharmaceuticals — US tariffs jeopardize medicine supply chains.

We explain how tariffs on low-margin generic drugs could quickly lead to supply shocks, turning essential medicines into a strategic tool of retaliation in trade conflicts — with real consequences for millions of patients.

Read the Letter! Our full, data-driven policy analysis is forthcoming.

If you are interested in learning more about our research on resilience go to our project page.

Authors: Giona Casiraghi, Georges Andres, and Frank Schweitzer, and Luca Verginer,